目的:评价telitacicept治疗系统性红斑狼疮患者血液学损害的疗效和安全性。
方法:本研究共纳入22例SLE和血液学受累患者。这些患者除接受标准治疗外还接受了Telitacicept。我们比较了他们的人口特征,临床表现,和治疗前后的实验室指标。
结果:共有22名患者接受了远程治疗,中位持续时间为10.4个月(6至19个月)。在telitacicept治疗之后,与基线相比,各种参数均有显著改善.具体来说,白细胞计数从(3.98±1.80)109/L增加到(6.70±2.47)109/L,(P=0.002),血红蛋白水平从(100±19)g/L增加到(125±22)g/L,(P<0.001),血小板计数从(83±60)109/L增加到(161±81)109/L,(P=0.004)。SLE疾病活动指数(SLEDAI)评分从12(5,15)降至0(0,4),(P<0.001)。此外,C3和C4水平显示出改善。Telitacicept治疗还导致血清IgG水平和每日泼尼松剂量的显着降低。治疗期间仅报告1起不良事件(4.5%),是尿路感染.
结论:telitacicept和标准治疗的组合显示贫血的显著改善,以及SLE和血液学受累患者的白细胞和血小板水平升高。重要的是,观察到的不良事件是可控的.要点•Telitacicept有效改善贫血,临床结果,并增加白细胞和血小板计数。•telitacicept治疗导致lgG水平降低,IgA,抗dsDNA,和SLEDAI得分,而血清补体C3和C4恢复正常。•在随访期间,观察到各个参数的变化,临床症状,和器官参与,均无明显不良事件。
OBJECTIVE: To evaluate the efficacy and safety of
telitacicept in SLE patients specifically with hematological involvement.
METHODS: A total of 22 patients with SLE and hematological involvement were included in this study. These patients received
telitacicept in addition to standard therapy. We compared their demographic characteristics, clinical manifestations, and laboratory indicators before and after the administration of telitacicept.
RESULTS: A total of 22 patients received
telitacicept treatment for a median duration of 10.4 months (ranging from 6 to 19 months). Following
telitacicept therapy, significant improvements were observed in various parameters compared to baseline. Specifically, white blood cell count increased from (3.98 ± 1.80) 109/L to (6.70 ± 2.47) 109/L, (P = 0.002), hemoglobin levels increased from (100 ± 19) g/L to (125 ± 22) g/L, (P < 0.001), and platelet count increased from (83 ± 60) 109/L to (161 ± 81) 109/L, (P = 0.004). SLE Disease Activity Index (SLEDAI) scores decreased from 12(5,15) to 0(0,4), (P < 0.001). Additionally, C3 and C4 levels showed improvement. Telitacicept treatment also resulted in a significant reduction in serum IgG levels and daily prednisone dosage. Only one adverse event (4.5%) was reported during the treatment, which was a urinary tract infection.
CONCLUSIONS: The combination of telitacicept and standard treatment demonstrated significant improvements in anemia, as well as increased leukocyte and platelet levels in patients with SLE and hematological involvement. Importantly, the observed adverse events were manageable and controllable. Key Points •
Telitacicept effectively improves anemia, clinical outcomes, and increases leukocyte and platelet counts. • Treatment with telitacicept leads to decreased levels of lgG, IgA, anti-dsDNA, and SLEDAI scores, while serum complement C3 and C4 returned to normal. • During the follow-up period there were observed changes in individual parameters, clinical symptoms, and organ involvement, all without significant adverse events.